Clinical Trial Update: Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating polyunsaturated fatty acids for fatty liver in diabetes has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Fatty Liver | Phase 2 | Status: COMPLETED | Results posted: 2018-02-23